Search

LY2275796

LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases. … LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.

Pozelimab

autoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

NGD-4715

NGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.

Morphine glucuronide

Odanacatib

Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. … The drug made it to phase III trials before abandoned due to increased stroke.

Methyl 2,5-dihydroxycinnamate

Ergothioneine

Cimicoxib

If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.

Oltipraz

Oltipraz has been used in trials studying the treatment and prevention of Lung Cancer, Liver Fibrosis, Liver Cirrhosis, and Non-alcoholic Fatty Liver Disease.

CEP-1347

CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons